Lecture
LED3 Lecture: The scientific origins of drugs that slow neurodegeneration & the structure-proteotoxicity relationship that emerges from clinical studies
- Date
- Monday 17 March 2025
- Time
- Location
-
Sylvius
Sylviusweg 72
2333 BE Leiden - Room
- 15.31
Prof. Kelly’s lab works at the forefront of the field of protein misfolding diseases, combining fundamental research into the molecular basis for misfolding and aggregation diseases with the development of innovative small molecule therapeutics.
Their pioneering approach to stabilize specific conformational states of proteins has led to the first FDA–approved drug (tafamadis), now sold by Pfizer, that slows the progression of an amyloid disease–transthyretin amyloidosis. They now strive to expand this concept to other protein misfolding diseases including light-chain amyloidosis and Alzheimer’s disease.